Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma

Cancer

Volumn 97, Issue 7, 2003, Pages 1758-1765

  Zhang, Fan ^a   Yang, Ying ^a   Smith, Terry ^a   Kau, Shu Wan ^a   McConathy, Judy M ^a   Esteva, Francisco J ^a   Kuerer, Henry M ^b   Fraser Symmans, W ^a   Buzdar, Aman U ^a   Hortobagyi, Gabriel N ^a   Pusztai, Lajos ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Anthracyclines; Clinical response; HER 2; Pathologic response; Preoperative chemotherapy

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; NEU DIFFERENTIATION FACTOR;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL FEATURE; CORRELATION COEFFICIENT; DIAGNOSTIC IMAGING; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; ONCOGENE NEU; PATHOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037377712     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11245     Document Type: Article

References (29)

1. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 1996;13:1359-1365.
2. Esteva FJ, Pusztai L, Symmans WF, Sneige N, Hortobagyi GN. Clinical relevance of HER-2 amplification and overexpression in human cancers. Ref Gynecol Obstet. 2000;7:267-276.
3. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in nodenegative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992;10:599-605.
4. Ménard S, Valagussa P, Pilotti S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol. 2001;19:329-335.
5. Miles DW, Harris WH, Gillett CE, Smith P, Barnes DM. Effect of c-erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer. 1999;84:354-359.
6. Seidman A, Baselga J, Yao TJ. HER-2/neu overexpression and clinical taxane sensitivity: a multivariate analysis in patients with metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol. 1996;15:104a.
7. Gianni L, Capri G, Mezzelani A. HER-2/neu amplification and response to doxorubicin/paclitaxel (AT) in women with metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol. 1997;16:139a.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
9. Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-1266.
10. Thor AD, Berry DA, Budman DR, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90:1346-1360.
11. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90:1320-1370.
12. Ravdin P, Green S, Albain K. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen alone [abstract]. Proc Am Soc Clin Oncol. 1998;17:97a.
13. Colozza M, Gori S, Mosconi A. c-erbB expression as a predictor of outcome in a randomized trial comparing adjuvant CMF vs. single agent epirubicin in Stage I-II breast cancer patients [abstract]. Proc Am Soc Clin Oncol. 1999;18:70a.
14. Rozan S, Vincent-Salomon A, Zafrani B, et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer. 1998;79:27-33.
15. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst. 2000;92:1991-1998.
16. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIa gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-flurorouracil. Clin Cancer Res. 2002;8:1107-1116.
17. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1998;17:460-469.
18. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-2685.
19. Ellis P, Smith I, Ashley S, et al. Clinical prognostic and predictive factors of primary chemotherapy in operable breast cancer. J Clin Oncol. 1998;16:107-114.
20. Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999;17:3058-3063.
21. Katz D, Baptista J, Azen SP, Pike MC. Obtaining confidence intervals for the risk ratio in cohort studies. Biometrics. 1978;34:469-474.
22. Petit T, Borel C, Ghnassia JP, et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res. 2001;7:1577-1581.
23. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res. 2002;8:1061-1067.
24. Wilt M, Millon R, Velten M, et al. Comparative value of SBR grade, hormonal receptors, KI 67, HER-2 and topo-isomerase II alpha (topo II alpha) status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy [abstract 123]. Proc Am Soc Clin Oncol. 2002;21:32a.
25. Tulbah AM, Ibrahim EM, Ezzat AA, et al. HER-2/neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer. Med Oncol. 2002;19:15-23.
26. Rouzier R, Extra J-M, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 2002;20:1304-1310.
27. Pegram MD, Ginn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 1997;15:537-547.
28. Jarvinen TAH, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase II associate with erbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156:839-847.
29. Harris LN, Yang L, Liotcheva V, et al. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res. 2001;7:1497-1504.